Previous studies have described an association of BRAF V600E mutation with aggressive features of PTC, including macroscopic extrathyroidal extension (ETE), lymph node metastasis (LNM), advanced stage, and disease recurrence [13–17, 21–23, 28]. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.